To develop strategies for preventing radiation-induced lung fibrosis (scarring), Vanderbilt investigators are exploring the cell types and factors that contribute to the fibrotic response.

Cancer investigators led by researchers at Vanderbilt-Ingram Cancer Center (VICC) have co-developed a liquid biopsy blood-based assay used to identify specific gene mutations associated with the development or relapse of small-cell lung cancer (SCLC).

Vanderbilt investigators have conducted a first-of-its-kind genome-wide association study of lung cancer survival in African-Americans.

Los Angeles native Christina Shaw had two powerful goals when she decided to move cross country to live in Nashville – the first was to support her favorite hockey team and the second was to meet a renowned lung cancer specialist at Vanderbilt-Ingram Cancer Center.

Researchers in the Schools of Medicine and Engineering at Vanderbilt University have discovered a proteomic “signature” from the airways of heavy smokers that could lead to better risk assessment and perhaps new ways to stop lung cancer before it starts.

Vanderbilt-Ingram Cancer Center (VICC) is leading a Phase 3 global trial of a cancer therapy that was initially tested and validated in a VICC research laboratory. One of the first patients treated with the therapy came to VICC after a bump on the head led to an unexpected cancer diagnosis.

Jonathan Lehman, M.D., Ph.D., instructor in Medicine in the Division of Hematology/Oncology, has received a Career Development Award from LUNGevity, a nonprofit organization that provides support programs for lung cancer patients and families, public education and funding for innovative scientific research.